Here’s a 10‑query test set you can drop into OpenEvidence.

## Easy (3)

1. “According to recent IDSA and SHEA guidelines, what is the preferred first‑line treatment for an initial episode of non‑fulminant Clostridioides difficile infection in adults, and how does it compare to vancomycin in terms of recurrence?”  

### Practice Guideline

  
For an initial episode of **non-fulminant Clostridioides difficile infection (CDI) in adults**, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) **recommend fidaxomicin as the preferred first-line treatment**, with a conditional recommendation and moderate certainty of evidence. The recommended dosage is fidaxomicin 200 mg orally twice daily for 10 days. **Vancomycin remains an acceptable alternative** if fidaxomicin is unavailable or resources are limited.[1]  
  
The rationale for this recommendation is that fidaxomicin and vancomycin have equivalent rates of initial clinical cure, but **fidaxomicin is associated with significantly lower rates of CDI recurrence** compared to vancomycin. Achieving sustained clinical response (initial cure without recurrence) is a key therapeutic goal, as recurrence is associated with decreased quality of life, increased healthcare costs, and risk of progression to severe disease. Fidaxomicin’s narrower spectrum of activity also preserves gut microbiota better than vancomycin, which may contribute to its lower recurrence rates. The guideline panel judged that the moderate improvement in sustained response and lack of increased adverse events or mortality favor fidaxomicin, despite its higher cost and potential access limitations.[1]  
  
In summary, **fidaxomicin is preferred over vancomycin for initial non-fulminant CDI due to lower recurrence rates**, but vancomycin is an acceptable alternative when fidaxomicin is not available.[1]  
  
  
Building on the consensus for first-line therapy, additional clinical trial data and meta-analyses further clarify the comparative efficacy of **fidaxomicin** and vancomycin for initial non-fulminant Clostridioides difficile infection. Multiple randomized controlled trials have demonstrated that while both agents achieve similar rates of initial clinical cure, **fidaxomicin consistently results in lower rates of CDI recurrence**. For example, a meta-analysis including over 3,900 patients found that fidaxomicin reduced the risk of recurrence by approximately 31% compared to vancomycin (risk ratio 0.69; 95% CI, 0.52–0.91), with recurrence rates of 16.1% for fidaxomicin versus 25.4% for vancomycin across diverse patient populations and clinical settings.[2] These findings are robust across subgroups, including those with initial CDI, first recurrence, and both non-severe and severe presentations.  
  
Other professional societies, such as the American College of Gastroenterology and the American Society of Colon and Rectal Surgeons, also recognize both fidaxomicin and vancomycin as first-line options, but highlight the superior sustained response and lower recurrence rates associated with fidaxomicin.[3][4] Cost and access remain practical considerations, as fidaxomicin’s higher acquisition cost may limit its use in some settings, despite evidence that reduced recurrence may offset these costs over time.[3]  
  
In summary, clinical trial and meta-analytic evidence strongly support **fidaxomicin** as the preferred first-line agent for initial non-fulminant CDI in adults, due to its lower recurrence rates compared to vancomycin, aligning with current guideline recommendations.[5][3][4][2]  
  
  
Would you like me to summarize the latest cost-effectiveness analyses comparing fidaxomicin and vancomycin for initial non-fulminant CDI, including considerations for healthcare resource utilization and long-term outcomes?  
  
### References

1. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides Difficile Infection in Adults. Johnson S, Lavergne V, Skinner AM, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549.
2. Path of Least Recurrence: A Systematic Review and Meta-Analysis of Fidaxomicin Versus Vancomycin for Clostridioides Difficile Infection. Liao JX, Appaneal HJ, Vicent ML, Vyas A, LaPlante KL. Pharmacotherapy. 2022;42(11):810-827. doi:10.1002/phar.2734.
3. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides Difficile Infections. Kelly CR, Fischer M, Allegretti JR, et al. The American Journal of Gastroenterology. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278.
4. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides Difficile Infection. Poylin V, Hawkins AT, Bhama AR, et al. Diseases of the Colon and Rectum. 2021;64(6):650-668. doi:10.1097/DCR.0000000000002047.
5. Recurrent Clostridioides difficile Infections. van Prehn J, Kuijper EJ, Dubberke ER. JAMA. 2025;:2840352. doi:10.1001/jama.2025.18089.

---------------------------

2. “What are the key CT findings that differentiate acute ischemic stroke from intracerebral hemorrhage on non‑contrast head CT, including the hyperdense MCA sign and loss of gray‑white differentiation?”  

On **non-contrast head computed tomography (CT)**, the key findings that differentiate **acute ischemic stroke** from **intracerebral hemorrhage** are as follows:  
  
**Acute ischemic stroke** is characterized by:  
  
- **Loss of gray-white differentiation**, especially in the insular cortex ("insular ribbon sign") and lentiform nucleus, which reflects early cytotoxic edema and is often seen within hours of onset.[1][2][3]  
  
- **Sulcal effacement** due to brain swelling.  
  
- **Hypoattenuation** (decreased density) in affected brain regions, which may be subtle early but becomes more apparent over time.[2][3]  
  
- The **hyperdense middle cerebral artery (MCA) sign**, which appears as a focal area of increased attenuation within the MCA on CT and indicates an intraluminal thrombus. This sign is highly specific for arterial occlusion but has limited sensitivity (approximately 30–52%). Its presence supports the diagnosis of large-vessel ischemic stroke.[1][2][4][5]  
  
**Intracerebral hemorrhage** is identified by:  
  
- **Hyperdense (bright) areas** on CT corresponding to acute blood within the brain parenchyma. This is the most reliable and immediate sign of hemorrhage.[6]  
  
- The hematoma may be surrounded by a rim of perihematomal edema, and may extend into the ventricles or subarachnoid space.[6]  
  
- There is no loss of gray-white differentiation in the early phase unless there is associated edema.  
  
In summary, **acute ischemic stroke** is suggested by **loss of gray-white differentiation**, **sulcal effacement**, **hypoattenuation**, and the **hyperdense MCA sign** (if present), whereas **intracerebral hemorrhage** is defined by a **hyperdense region** representing acute blood.[1][2][4][6][5][3] CT is highly sensitive for hemorrhage and is the imaging modality of choice for rapid differentiation in the acute setting.  
  
  
Would you like me to summarize the sensitivity and specificity of these CT findings—particularly the hyperdense MCA sign and loss of gray-white differentiation—for diagnosing acute ischemic stroke versus intracerebral hemorrhage, based on current literature?  
  
### References

1. Established Treatments for Acute Ischaemic Stroke. Khaja AM, Grotta JC. Lancet (London, England). 2007;369(9558):319-30. doi:10.1016/S0140-6736(07)60154-8.
2. Imaging of Acute Stroke. Muir KW, Buchan A, von Kummer R, Rother J, Baron JC. The Lancet. Neurology. 2006;5(9):755-68. doi:10.1016/S1474-4422(06)70545-2.
3. Acute Ischemic Stroke. van der Worp HB, van Gijn J. The New England Journal of Medicine. 2007;357(6):572-9. doi:10.1056/NEJMcp072057.
4. Sensitivity and Specificity of the Hyperdense Artery Sign for Arterial Obstruction in Acute Ischemic Stroke. Mair G, Boyd EV, Chappell FM, et al. Stroke. 2015;46(1):102-7. doi:10.1161/STROKEAHA.114.007036.
5. Prevalence and Significance of Hyperdense Middle Cerebral Artery in Acute Stroke. Leys D, Pruvo JP, Godefroy O, Rondepierre P, Leclerc X. Stroke. 1992;23(3):317-24. doi:10.1161/01.str.23.3.317.
6. Spontaneous Intracerebral Hemorrhage. Sheth KN. The New England Journal of Medicine. 2022;387(17):1589-1596. doi:10.1056/NEJMra2201449.

-------------------------------

3. “For a patient with newly diagnosed HFrEF (LVEF ≤40%), what do current ESC/ACC/AHA guidelines recommend as foundational pharmacologic therapy (drug classes and sequence)?”  


### Practice Guideline

  
For a patient with newly diagnosed heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%), the American College of Cardiology and American Heart Association, as well as the European Society of Cardiology, recommend initiating **four foundational drug classes**: an angiotensin receptor–neprilysin inhibitor (ARNI; preferred), or an ACE inhibitor/ARB if ARNI is contraindicated or unavailable; a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol); a mineralocorticoid receptor antagonist (MRA; spironolactone or eplerenone); and a sodium-glucose cotransporter 2 (SGLT2) inhibitor (dapagliflozin, empagliflozin, or sotagliflozin).[1]  
  
The recommended approach is to **initiate all four classes as early and rapidly as tolerated**, ideally within three months, rather than sequentially titrating each to target before starting the next. The rationale, as stated by the American College of Cardiology and American Heart Association, is that early use of all four classes confers maximal reduction in morbidity and mortality, as supported by randomized trial data. There is no universally optimal sequence; therapy should be individualized based on clinical status, blood pressure, renal function, and tolerability. Loop diuretics are used for symptomatic congestion but do not confer mortality benefit and are not considered foundational.[1]  
  
Typical starting dosages are: sacubitril/valsartan 24/26 mg twice daily (ARNI), carvedilol 3.125 mg twice daily or metoprolol succinate 12.5–25 mg daily (beta-blocker), spironolactone 12.5–25 mg daily (MRA), and dapagliflozin or empagliflozin 10 mg daily (SGLT2 inhibitor).[1] The societies recommend titrating to maximally tolerated or target doses as soon as safely possible.[1]  
  
  
Building on the foundational quadruple therapy, recent systematic reviews and meta-analyses confirm that the combination of **ARNI (sacubitril/valsartan), beta-blocker, MRA, and SGLT2 inhibitor** provides additive and early reductions in mortality and heart failure hospitalizations, with benefits apparent within days to weeks of initiation.[2][3] The optimal strategy is to start all four classes as soon as tolerated, rather than titrating each to target before adding the next, as delaying any component exposes patients to unnecessary risk. [3][4]  
  
Loop diuretics remain essential for symptomatic relief of congestion but do not confer mortality benefit and should be adjusted based on volume status.[5][6] For patients unable to tolerate ARNI, ACE inhibitors or ARBs are recommended as alternatives, and hydralazine/isosorbide dinitrate may be considered in Black patients with persistent symptoms despite optimal therapy.[5] Dosage for SGLT2 inhibitors is standardized at **10 mg daily** for dapagliflozin or empagliflozin, as supported by regulatory approval and clinical trial data. [7][2]  
  
Additional agents such as vericiguat and omecamtiv mecarbil may be considered in select patients with persistent symptoms or high risk, but are not part of the initial foundational regimen.[2][3] The consensus across the medical literature is that **early, simultaneous initiation and rapid uptitration of the four foundational drug classes** is the evidence-based approach for newly diagnosed HFrEF, with therapy individualized to patient tolerability and comorbidities.[4][2][6]  
  
  
Would you like me to summarize the latest evidence and guideline recommendations regarding the management of patients who cannot tolerate one or more of the foundational drug classes, including alternative therapies and sequencing strategies?  
  
### References

1. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Maddox TM, Januzzi JL, Allen LA, et al. Journal of the American College of Cardiology. 2024;83(15):1444-1488. doi:10.1016/j.jacc.2023.12.024.
2. Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis. van Essen BJ, Ceelen DCH, Ouwerkerk W, et al. Journal of the American College of Cardiology. 2025;86(24):2513-2526. doi:10.1016/j.jacc.2025.08.054.
3. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3. Greene SJ, Bauersachs J, Brugts JJ, et al. Journal of the American College of Cardiology. 2023;82(6):559-571. doi:10.1016/j.jacc.2023.04.057.
4. Heart Failure With Reduced Ejection Fraction. Cannata A, Crespo-Leiro MG, Bromage DI, Ruschitzka F, McDonagh TA. Lancet (London, England). 2025;:S0140-6736(25)01851-3. doi:10.1016/S0140-6736(25)01851-3.
5. Heart Failure With Reduced Ejection Fraction: A Review. Murphy SP, Ibrahim NE, Januzzi JL. JAMA. 2020;324(5):488-504. doi:10.1001/jama.2020.10262.
6. Heart Failure Pharmacotherapy. Lisi DL, Gaddis K, Abdou MH. The Medical Clinics of North America. 2025;109(6):1219-1239. doi:10.1016/j.mcna.2025.04.003.
7. FDA Orange Book. FDA Orange Book.

---------------------------------------------------------------------------------------
## Medium (3)

4. “Compare apixaban and rivaroxaban for stroke prevention in non‑valvular atrial fibrillation, focusing on efficacy, major bleeding risk, and key differences in patients with moderate chronic kidney disease (eGFR 30–50 mL/min).”  

### Practice Guideline

  
For stroke prevention in patients with non-valvular atrial fibrillation, both **apixaban and rivaroxaban are effective direct oral anticoagulants (DOACs)**. The American College of Cardiology, American Heart Association, and American College of Chest Physicians recommend either agent for most patients, but highlight important differences in safety and renal dosing.[1]  
  
**Efficacy for stroke prevention is similar** between apixaban and rivaroxaban in the general population with non-valvular atrial fibrillation.[1] However, **apixaban is associated with a lower risk of major bleeding** compared to rivaroxaban, particularly gastrointestinal bleeding, as supported by both randomized trials and large observational studies.[1]  
  
In patients with **moderate chronic kidney disease (eGFR 30–50 mL/min)**, both drugs are approved and effective. The American College of Cardiology and American Heart Association note that **apixaban maintains efficacy and safety in CKD stage 3 (eGFR 30–60 mL/min)**, with pivotal trials showing similar stroke prevention and bleeding rates as in patients with normal renal function.[1] Apixaban’s pharmacokinetics are less affected by renal impairment, and it is preferred in patients with higher bleeding risk or more advanced CKD. Rivaroxaban is also used in this population, but has a higher proportion of renal excretion and may be associated with more bleeding events.  
  
**Key differences**: Apixaban is preferred in patients with moderate CKD due to its lower bleeding risk and stable efficacy, while rivaroxaban remains an alternative but may carry a higher risk of major bleeding in this group.[1] Dosage adjustments for both agents are required based on renal function, but apixaban’s safety profile is more favorable in CKD.  
  
  
Expanding on these points, large-scale comparative effectiveness studies and meta-analyses consistently demonstrate that **apixaban is associated with a lower risk of major bleeding, including gastrointestinal bleeding, compared to rivaroxaban**, while maintaining at least equivalent efficacy for stroke prevention in patients with non-valvular atrial fibrillation.[2][3][4][5][6] For example, a meta-analysis of real-world studies found a significantly lower hazard of major bleeding with apixaban (HR 0.62, 95% CI 0.56–0.69) and a lower risk of stroke or systemic embolism (HR 0.88, 95% CI 0.81–0.95) compared to rivaroxaban.[3] These findings are corroborated by large cohort studies in routine clinical practice.[4][5]  
  
In patients with **moderate chronic kidney disease (eGFR 30–50 mL/min)**, both agents are approved and effective, but the safety advantage of apixaban persists. Subgroup analyses show that **apixaban’s lower bleeding risk compared to rivaroxaban is maintained in patients with CKD**, including those with eGFR 30–50 mL/min.[2][5][6] Pharmacokinetic data indicate that apixaban has less renal excretion (approximately 25%) than rivaroxaban (approximately 36%), which may contribute to its more favorable bleeding profile in CKD.[7][8] Both drugs require dose adjustment in this population: apixaban is typically dosed at 5 mg twice daily (reduced to 2.5 mg twice daily if two or more dose-reduction criteria are met), while rivaroxaban is dosed at 15 mg once daily for eGFR 15–50 mL/min.[8][9]  
  
In summary, **apixaban is favored over rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation and moderate CKD due to a lower risk of major bleeding with similar efficacy**, and this advantage is consistent across standard and reduced dosing regimens.[2][3][4][5][6]  
  
  
Would you like me to summarize the latest head-to-head randomized controlled trials or real-world comparative studies specifically focusing on apixaban versus rivaroxaban in patients with moderate CKD, to clarify if these safety and efficacy differences persist across diverse populations and dosing regimens?  
  
### References

1. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Joglar JA, Chung MK, et al. Journal of the American College of Cardiology. 2024;83(1):109-279. doi:10.1016/j.jacc.2023.08.017.
2. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. Lau WCY, Torre CO, Man KKC, et al. Annals of Internal Medicine. 2022;175(11):1515-1524. doi:10.7326/M22-0511.
3. Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. Mamas MA, Batson S, Pollock KG, et al. The American Journal of Cardiology. 2022;166:58-64. doi:10.1016/j.amjcard.2021.11.021.
4. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. Ray WA, Chung CP, Stein CM, et al. JAMA. 2021;326(23):2395-2404. doi:10.1001/jama.2021.21222.
5. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Fralick M, Colacci M, Schneeweiss S, et al. Annals of Internal Medicine. 2020;172(7):463-473. doi:10.7326/M19-2522.
6. Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Zhu W, Ye Z, Chen S, et al. Stroke. 2021;52(4):1225-1233. doi:10.1161/STROKEAHA.120.031007.
7. Atrial Fibrillation and Thromboembolism In Patients With Chronic Kidney Disease. Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Journal of the American College of Cardiology. 2016;68(13):1452-1464. doi:10.1016/j.jacc.2016.06.057.
8. Nonvitamin K Anticoagulant Agents In Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. Chan KE, Giugliano RP, Patel MR, et al. Journal of the American College of Cardiology. 2016;67(24):2888-99. doi:10.1016/j.jacc.2016.02.082.
9. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. Kumar S, Lim E, Covic A, et al. Journal of the American College of Cardiology. 2019;74(17):2204-2215. doi:10.1016/j.jacc.2019.08.1031.

-------------------------


5. “In adults with moderate‑to‑severe ulcerative colitis who have failed anti‑TNF therapy, what do recent ACG/ECCO guidelines recommend regarding the choice between vedolizumab and ustekinumab, and what are the main differences in efficacy and safety?”  

### Practice Guideline

  
For adults with moderate to severe ulcerative colitis who have not responded to anti–tumor necrosis factor (anti-TNF) therapy, the American College of Gastroenterology and the European Crohn’s and Colitis Organisation recommend switching to a therapy with a different mechanism of action, specifically either **vedolizumab or ustekinumab**.[1] Both agents are considered appropriate options in this setting.  
  
The American College of Gastroenterology notes that **ustekinumab demonstrates a likely important benefit over vedolizumab in achieving clinical remission and endoscopic improvement** in patients previously exposed to anti-TNF agents, based on network meta-analyses and indirect comparisons.[2] Ustekinumab induction (6 mg/kg IV) and maintenance (90 mg SC every 8 weeks) are associated with higher rates of clinical and endoscopic remission compared to placebo, with rapid symptom improvement and a favorable safety profile.[1] Vedolizumab is effective, but response rates are lower in anti-TNF–experienced patients compared to anti-TNF–naive patients.[1]  
  
In terms of safety, both vedolizumab and ustekinumab have low rates of serious adverse events and infections, with no significant differences in safety between the two agents in clinical trials.[1] Vedolizumab is gut-selective, which may further reduce systemic immunosuppression risk, while ustekinumab has demonstrated sustained benefit and low immunogenicity.  
  
In summary, **ustekinumab is likely to be more effective than vedolizumab for anti-TNF–experienced moderate to severe ulcerative colitis**, but both are safe and reasonable choices according to the American College of Gastroenterology and European Crohn’s and Colitis Organisation guidelines.[1][2]  
  
  
Building on the guideline recommendations, recent comparative effectiveness studies and network meta-analyses provide further insight into the choice between **vedolizumab** and **ustekinumab** for adults with moderate to severe ulcerative colitis who have failed anti-TNF therapy. Real-world cohort data and indirect comparisons indicate that both agents achieve similar rates of steroid-free clinical remission, mucosal healing, and treatment persistence in anti-TNF–experienced patients, with no statistically significant difference in hospitalization, colectomy, or serious/infectious adverse events between the two drugs.[3][4] However, some analyses suggest numerically higher rates of target outcomes—including mucosal healing and steroid-free remission—with **ustekinumab** compared to **vedolizumab**, though these differences have not reached statistical significance and require confirmation in prospective head-to-head trials.[4]  
  
Network meta-analyses rank **ustekinumab** among the most effective advanced therapies for induction of clinical remission in biologic-exposed ulcerative colitis, with efficacy comparable to or exceeding that of vedolizumab, especially for induction endpoints.[5][6] For maintenance of remission and histologic healing, **vedolizumab** is often ranked highly, but again, direct comparisons do not show significant differences in efficacy or safety.[6] Both agents have favorable safety profiles, with low rates of serious infections and malignancy, and minimal immunogenicity.[7]  
  
In summary, while **ustekinumab may offer a modest efficacy advantage for induction of remission in anti-TNF–experienced ulcerative colitis**, both **vedolizumab and ustekinumab are considered safe and effective options**, and the choice should be individualized based on patient comorbidities, route of administration preference, and prior response patterns.[3][5][6][7][4]  
  
  
Would you like me to summarize the latest head-to-head clinical trial data (if available) or ongoing studies directly comparing vedolizumab and ustekinumab in anti-TNF–experienced ulcerative colitis patients, to clarify any emerging differences in efficacy or safety?  
  
### References

1. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. The American Journal of Gastroenterology. 2025;120(6):1187-1224. doi:10.14309/ajg.0000000000003463.
2. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Singh S, Loftus EV, Limketkai BN, et al. Gastroenterology. 2024;167(7):1307-1343. doi:10.1053/j.gastro.2024.10.001.
3. Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients With Ulcerative Colitis: A GETAID Multicentre Cohort Study. Meyer A, Fumery M, Peyrin-Biroulet L, et al. Scandinavian Journal of Gastroenterology. 2022;57(12):1454-1462. doi:10.1080/00365521.2022.2095668.
4. Effectiveness of Vedolizumab and Ustekinumab as Second Biologic Agent in Achieving Target Outcomes in Tumor Necrosis Factor Antagonists Experienced Patients With Inflammatory Bowel Disease (Enroll-Ex Study). Alrashed F, Abdullah I, Alfadhli A, Shehab M. Frontiers in Pharmacology. 2023;14:1243080. doi:10.3389/fphar.2023.1243080.
5. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Ananthakrishnan AN, Murad MH, Scott FI, et al. Gastroenterology. 2024;167(7):1460-1482. doi:10.1053/j.gastro.2024.07.046.
6. An Indirect Comparison of Efficacy Including Histologic Assessment and Safety in Biologic Therapy in Ulcerative Colitis: Systemic Review and Network Meta-Analysis. Chae K, Seo YS, Yu YM, Chang MJ, Choi J. PloS One. 2023;18(11):e0293655. doi:10.1371/journal.pone.0293655.
7. Ulcerative Colitis in Adults: A Review. Gros B, Kaplan GG. JAMA. 2023;330(10):951-965. doi:10.1001/jama.2023.15389.

------------------------------------------

6. “For post‑menopausal women with early‑stage, hormone receptor‑positive, HER2‑negative breast cancer, how do current ASCO/ESMO guidelines recommend using genomic assays (e.g., Oncotype DX, MammaPrint) to guide decisions about adjuvant chemotherapy?”  

For post-menopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer, the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines recommend the use of genomic assays—specifically **Oncotype DX** and **MammaPrint**—to guide decisions regarding adjuvant chemotherapy in select clinical scenarios.[1]  
  
Guideline Overview and Patient Population  
  
Both ASCO and ESMO support genomic testing for post-menopausal women (or age >50 years) with early-stage, ER-positive, HER2-negative breast cancer, particularly in those with node-negative or 1–3 node-positive disease. Clinical risk is defined by tumor size, grade, and other pathological features, and is used in conjunction with node status and menopausal status to determine the appropriateness of genomic testing.[1][2] These assays are not recommended for HER2-positive or triple-negative disease.  
  
Oncotype DX—Indications, Interpretation, and Chemotherapy Guidance  
  
**Oncotype DX** is recommended for post-menopausal women with node-negative or 1–3 node-positive, ER-positive, HER2-negative breast cancer.  [1]  
  
- For node-negative disease, Oncotype DX recurrence score (RS) [1][3]  
  
- For 1–3 node-positive disease, the RxPONDER trial demonstrated that post-menopausal women with RS 0–25 do not benefit from adjuvant chemotherapy, and endocrine therapy alone is sufficient.  [1][4][2]  
  
- The TAILORx trial further supports withholding chemotherapy in post-menopausal women with intermediate RS (11–25).  [1][3]  
  
- Use of Oncotype DX in these populations has led to a substantial reduction in chemotherapy recommendations, supporting its utility in clinical decision-making.[4]  
  
MammaPrint—Indications, Clinical Risk, and Chemotherapy Guidance  
  
**MammaPrint** is recommended for post-menopausal women with high clinical risk, node-negative or 1–3 node-positive, ER-positive, HER2-negative breast cancer.  [1][3]  
  
- The MINDACT trial showed that post-menopausal women with high clinical risk but low genomic risk by MammaPrint do not derive significant benefit from adjuvant chemotherapy; endocrine therapy alone is appropriate.  [2][1][3]  
  
- MammaPrint is not recommended for patients with low clinical risk, regardless of node status, or for those with ≥4 positive nodes due to insufficient evidence of clinical utility.[1][3]  
  
Shared Decision-Making and Other Assays  
  
Guidelines emphasize the importance of shared decision-making, incorporating patient preferences, comorbidities, and multidisciplinary input.[2][3] Other assays (Prosigna, EndoPredict, Breast Cancer Index) may be considered, but have less robust prospective data and are generally reserved for node-negative disease or specific scenarios.[1][2]  
  
Gaps and Future Directions  
  
There is a lack of prospective randomized data for the use of genomic assays in patients with ≥4 positive nodes, and for some assays in node-positive disease.[1][4][2] The predictive value of these tests in post-menopausal women with node-positive disease is supported by RxPONDER and MINDACT, but evidence is weaker for other assays and for more extensive nodal involvement.  
  
In summary, **ASCO and ESMO guidelines recommend Oncotype DX and MammaPrint to guide adjuvant chemotherapy decisions in post-menopausal women with early-stage, HR-positive, HER2-negative breast cancer who are node-negative or have 1–3 positive nodes, with chemotherapy generally omitted in those with low genomic risk**. Clinical risk, node status, and menopausal status are critical in assay selection and interpretation. Shared decision-making remains essential, and the use of other assays should be individualized based on available evidence.  
  
  
Would you like me to summarize the latest evidence comparing long-term outcomes—such as overall survival and distant recurrence rates—between patients managed with genomic assay-guided chemotherapy decisions versus traditional clinicopathologic risk assessment alone? This could help clarify the real-world impact of these assays on patient prognosis.  
  
### References

1. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Andre F, Ismaila N, Allison KH, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2022;40(16):1816-1837. doi:10.1200/JCO.22.00069.
2. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. Raab R, Ismaila N, Andre F, Stearns V, Kalinsky K. JCO Oncology Practice. 2022;18(9):646-648. doi:10.1200/OP.22.00230.
3. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. Henry NL, Somerfield MR, Abramson VG, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2019;37(22):1965-1977. doi:10.1200/JCO.19.00948.
4. Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review. Cooper K, Nalbant G, Essat M, et al. Breast Cancer Research and Treatment. 2025;210(2):229-247. doi:10.1007/s10549-024-07596-0.

------------------------------------------------------------------------------------------
## Hard (4)

7. “In patients with metastatic non‑small cell lung cancer, EGFR exon 20 insertion mutations, and no prior targeted therapy, how do current guidelines and key trials position amivantamab versus mobocertinib, including efficacy, toxicity, and sequencing with platinum‑based chemotherapy and immunotherapy?”  

**EGFR exon 20 insertion mutations account for approximately 1–10% of EGFR-mutated metastatic non-small cell lung cancer (NSCLC) and confer intrinsic resistance to conventional EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib, which are largely ineffective in this molecular subset**.[1][2][3] Historically, platinum-based chemotherapy was the standard first-line therapy, but outcomes were suboptimal, prompting the development of targeted agents specifically for EGFR exon 20 insertions.[1][2][3]  
  
**Current guidelines from the American Society of Clinical Oncology (ASCO) 2024.2 recommend first-line therapy with amivantamab plus platinum-pemetrexed chemotherapy for patients with metastatic NSCLC harboring EGFR exon 20 insertion mutations who have not received prior targeted therapy**.[4] The FDA has approved amivantamab in combination with carboplatin and pemetrexed for this indication, as well as mobocertinib for patients who have progressed after platinum-based chemotherapy.[5][6] Mobocertinib is not currently recommended as first-line therapy due to lack of superiority over chemotherapy in phase 3 trials.[7]  
  
In the phase 3 PAPILLON trial, **amivantamab plus platinum-pemetrexed chemotherapy demonstrated superior efficacy compared to chemotherapy alone** in treatment-naive patients with EGFR exon 20 insertion NSCLC. Median progression-free survival (PFS) was 11.4 months with amivantamab–chemotherapy versus 6.7 months with chemotherapy alone (HR 0.40, 95% CI 0.30–0.53; P[8] These results establish amivantamab plus chemotherapy as the preferred first-line regimen.  
  
In contrast, the phase 3 EXCLAIM-2 trial found that **mobocertinib did not improve PFS or ORR compared to platinum-based chemotherapy in the first-line setting** (median PFS 9.6 months for both arms; HR 1.04, 95% CI 0.77–1.39; ORR 32% vs 30%).[7] While mobocertinib showed a longer median duration of response (12.0 vs 8.4 months), it failed to meet the primary endpoint and is not recommended as initial therapy.[7] Indirect comparisons in platinum-pretreated patients suggest similar time-to-event efficacy for amivantamab and mobocertinib, but amivantamab may have a higher response rate and more favorable safety profile.[9][10][11]  
  
**Amivantamab is associated with infusion-related reactions (66%), rash (86%), paronychia (45%), and reversible hematologic toxicities; 7% of patients discontinued due to adverse events in the PAPILLON trial**.[12][13] Most infusion reactions occur during the first administration and are manageable with premedication and slower infusion rates.[12] Mobocertinib, an oral TKI, is characterized by high rates of diarrhea (up to 93%), rash (38–45%), paronychia (38%), and risk of QTc prolongation, necessitating cardiac monitoring and dose reductions in some patients.[6][5] Comparative analyses indicate that **amivantamab has a more favorable safety profile, with fewer severe gastrointestinal and cardiac toxicities than mobocertinib**.[9][10][11]  
  
**Sequencing recommendations per ASCO and trial data are as follows: amivantamab plus platinum-pemetrexed chemotherapy is the preferred first-line regimen for EGFR exon 20 insertion NSCLC. Mobocertinib is reserved for patients who progress after platinum-based chemotherapy and amivantamab, or who are ineligible for amivantamab**.[4][8][7][14] Immunotherapy (PD-1/PD-L1 inhibitors) has limited efficacy in this molecular subset and is not recommended as monotherapy or in combination with chemotherapy in EGFR-mutant NSCLC, including exon 20 insertions.[4][14] Molecular profiling using next-generation sequencing and FDA-approved companion diagnostics is essential for identifying eligible patients.[2][12]  
  
In summary, **amivantamab plus platinum-pemetrexed chemotherapy is the recommended first-line therapy for metastatic NSCLC with EGFR exon 20 insertion mutations, offering superior efficacy and a more favorable safety profile compared to mobocertinib and chemotherapy alone. Mobocertinib is not recommended as initial therapy but may be considered post-platinum and post-amivantamab. Immunotherapy is not effective in this setting**.  
  
  
Would you like me to summarize the latest data on resistance mechanisms to amivantamab in EGFR exon 20 insertion NSCLC, and review emerging strategies or agents being investigated for patients who progress after first-line amivantamab plus chemotherapy?  
  
### References

1. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. Seo D, Lim JH. International Journal of Molecular Sciences. 2024;25(11):5917. doi:10.3390/ijms25115917.
2. Optimizing Diagnosis and Treatment of EGFR Exon 20 Insertions Mutant NSCLC. Passiglia F, Malapelle U, Normanno N, Pinto C. Cancer Treatment Reviews. 2022;109:102438. doi:10.1016/j.ctrv.2022.102438.
3. EGFR Exon 20 Insertions in NSCLC: From Biology to Amivantamab, Optimal Treatment Strategy and Emerging Therapeutics. Furuya N. Future Oncology (London, England). 2025;:1-10. doi:10.1080/14796694.2025.2550927.
4. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. Bazhenova L, Ismaila N, Abu Rous F, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2024;42(36):e72-e86. doi:10.1200/JCO-24-02133.
5. FDA Orange Book. FDA Orange Book.
6. Characterization and Management of Adverse Events Observed With Mobocertinib (TAK-788) Treatment for  Exon 20 Insertion-Positive Non-Small Cell Lung Cancer. Yang JC, Zhou C, Jänne PA, et al. Expert Review of Anticancer Therapy. 2023;23(1):95-106. doi:10.1080/14737140.2023.2157815.
7. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2025;43(13):1553-1563. doi:10.1200/JCO-24-01269.
8. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. Zhou C, Tang KJ, Cho BC, et al. The New England Journal of Medicine. 2023;389(22):2039-2051. doi:10.1056/NEJMoa2306441.
9. Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer. Kim TM, Girard N, Leighl NB, et al. Future Oncology (London, England). 2024;20(8):447-458. doi:10.2217/fon-2023-0620.
10. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Ou SI, Prawitz T, Lin HM, et al. Clinical Lung Cancer. 2024;25(3):e145-e152.e3. doi:10.1016/j.cllc.2023.11.011.
11. Targeting EGFR Exon 20 Insertion Mutation in Non-Small Cell Lung Cancer: Amivantamab and Mobocertinib. Russell MC, Garelli AM, Reeves DJ. The Annals of Pharmacotherapy. 2023;57(2):198-206. doi:10.1177/10600280221098398.
12. FDA Approval Summary: Amivantamab for the Treatment of Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations. Chon K, Larkins E, Chatterjee S, et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2023;29(17):3262-3266. doi:10.1158/1078-0432.CCR-22-3713.
13. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Park K, Haura EB, Leighl NB, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2021;39(30):3391-3402. doi:10.1200/JCO.21.00662.
14. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. Zhou C, Ramalingam SS, Kim TM, et al. JAMA Oncology. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761.

---------------------------------------

8. “For type 2 diabetes with established ASCVD and CKD (eGFR 25–45 mL/min), what is the recommended combination and sequencing of SGLT2 inhibitors and GLP‑1 receptor agonists according to ADA and KDIGO guidance, and how should therapy be adjusted as eGFR declines below 30?”  

### Practice Guideline

  
For a patient with type 2 diabetes, established atherosclerotic cardiovascular disease, and chronic kidney disease (eGFR 25–45 mL/min), the American Diabetes Association and Kidney Disease: Improving Global Outcomes guidelines recommend **initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) with proven cardiovascular and kidney benefit as first-line therapy for organ protection, provided eGFR is ≥20 mL/min/1.73 m²**.[1][2] SGLT2i should be continued as eGFR declines, as their cardiorenal benefits persist even when glycemic efficacy wanes below eGFR 45 mL/min/1.73 m². [3][1][2]  
  
**Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with demonstrated cardiovascular benefit are recommended as add-on therapy for further cardiovascular risk reduction and glycemic control, especially if glycemic targets are not met or SGLT2i are contraindicated or not tolerated**.[1][3][2] GLP-1 RAs retain glucose-lowering efficacy and cardiovascular benefit at low eGFR, including [1][2]  
  
**Sequencing should prioritize SGLT2i initiation first, followed by GLP-1 RA if additional glycemic or cardiovascular benefit is needed**.[1][2] As eGFR falls below 30 mL/min/1.73 m², SGLT2i should be continued if already established and tolerated, but not newly initiated below eGFR 20 mL/min/1.73 m². GLP-1 RAs remain appropriate and effective at all stages of CKD, including advanced CKD and dialysis.[1][2]  
  
These recommendations are justified by robust evidence for SGLT2i and GLP-1 RA in reducing CKD progression, major adverse cardiovascular events, and heart failure, independent of glycemic effects, and by their safety profiles in advanced CKD.[1][3][2]  
  
  
Building on these recommendations, the clinical trial evidence and regulatory approvals for individual agents further clarify the therapeutic approach. Among SGLT2 inhibitors, **canagliflozin and dapagliflozin are approved for use in patients with type 2 diabetes and CKD down to an eGFR of 20 mL/min/1.73 m², and should be continued for kidney and cardiovascular protection even as eGFR declines below 30 mL/min/1.73 m², unless dialysis is initiated**.[4][5] The Kidney Disease: Improving Global Outcomes guideline specifically states that SGLT2 inhibitors may be continued below their initiation threshold, referencing the CREDENCE and DAPA-CKD trials, which demonstrated sustained cardiorenal benefits in advanced CKD.[5]  
  
For GLP-1 receptor agonists, **semaglutide and dulaglutide are approved for cardiovascular risk reduction in type 2 diabetes with established ASCVD, and semaglutide is also indicated for CKD progression risk reduction**.[4] These agents retain efficacy and safety at eGFR [4][5] The KDIGO guideline highlights that GLP-1 RAs are generally preferred for additional glycemic control and ASCVD risk reduction, and may be initiated or continued at any stage of CKD, including eGFR [5]  
  
As eGFR falls below 30 mL/min/1.73 m², **SGLT2 inhibitors should not be newly initiated but may be continued if already established, while GLP-1 receptor agonists remain appropriate for both glycemic and cardiovascular benefit**.[5][6] The American Heart Association notes that GLP-1 RAs have a favorable safety profile in advanced CKD and may be preferred as renal function declines, especially when SGLT2i initiation is no longer possible.[6]  
  
In summary, **initiate and continue SGLT2 inhibitors for cardiorenal protection if eGFR ≥20 mL/min/1.73 m², add GLP-1 receptor agonists for further ASCVD and glycemic benefit, and prioritize GLP-1 RAs as eGFR declines below 30 mL/min/1.73 m²**. Therapy should be individualized based on tolerability, comorbidities, and patient preferences, with careful adjustment of concomitant hypoglycemic agents to minimize risk.[5][6]  
  
  
Would you like me to summarize the latest head-to-head clinical trial data comparing the efficacy and safety of specific SGLT2 inhibitors versus GLP-1 receptor agonists in patients with advanced CKD (eGFR Diabetes Management in Chronic Kidney Disease: A consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). de Boer IH, Khunti K, Sadusky T, et al. Kidney International. 2022;102(5):974-989. doi:10.1016/j.kint.2022.08.012.
2. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S239-S251. doi:10.2337/dc25-S011.
3. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S181-S206. doi:10.2337/dc25-S009.
4. FDA Orange Book. FDA Orange Book.
5. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). Michel Jadoul, Mustafa Arici, Gloria Ashuntantang, et al. Kidney Disease: Improving Global Outcomes.
6. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Rangaswami J, Bhalla V, de Boer IH, et al. Circulation. 2020;142(17):e265-e286. doi:10.1161/CIR.0000000000000920.

------------------------------------------

9. “How do recent AHA/ASA guidelines compare tenecteplase versus alteplase for acute ischemic stroke thrombolysis, including dose, indications, non‑inferiority/superiority data, and specific scenarios where tenecteplase is preferred or not recommended?”  

Recent American Heart Association/American Stroke Association guidelines state that **tenecteplase (0.25 mg/kg IV bolus, maximum 25 mg) is non-inferior to alteplase (0.9 mg/kg IV, 10% bolus then 90% infusion over 1 hour, maximum 90 mg) for intravenous thrombolysis in acute ischemic stroke within 4.5 hours of symptom onset**.[1][2][3][4] Both agents yield similar rates of excellent functional outcome (modified Rankin Scale 0–1 at 90 days) and comparable safety profiles, including rates of symptomatic intracerebral hemorrhage and mortality.[2][3][4]  
  
**Tenecteplase is preferred over alteplase in clinical scenarios where rapid administration is critical, such as prehospital thrombolysis, interhospital transfer, or when endovascular thrombectomy is planned, due to its single-bolus dosing and logistical advantages**.[2][5][6] In patients with large vessel occlusion, tenecteplase may offer higher early recanalization rates, though superiority for long-term outcomes has not been consistently demonstrated.[2][6]  
  
Tenecteplase is **not recommended at doses higher than 0.25 mg/kg** (e.g., 0.4 mg/kg), as higher doses are associated with increased risk of symptomatic intracerebral hemorrhage and worse outcomes.[6] Alteplase remains the standard for patients with contraindications to tenecteplase or in settings where tenecteplase is not available or approved for stroke.[5][1]  
  
In summary, **tenecteplase 0.25 mg/kg is a guideline-endorsed alternative to alteplase for acute ischemic stroke thrombolysis, with similar efficacy and safety, and is preferred in scenarios requiring rapid, simple administration or when endovascular therapy is planned**.[2][3][4][6]  
  
  
Would you like me to summarize the latest clinical trial data comparing tenecteplase and alteplase specifically in patients with large vessel occlusion undergoing endovascular thrombectomy, to clarify if tenecteplase offers any advantage in early recanalization or functional outcomes in this subgroup?  
  
### References

1. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. Warach SJ, Ranta A, Kim J, et al. JAMA Neurology. 2023;80(7):732-738. doi:10.1001/jamaneurol.2023.1449.
2. Tenecteplase Versus Alteplase for Acute Stroke Within 4·5 H of Onset (ATTEST-2): A Randomised, Parallel Group, Open-Label Trial. Muir KW, Ford GA, Ford I, et al. The Lancet. Neurology. 2024;23(11):1087-1096. doi:10.1016/S1474-4422(24)00377-6.
3. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. Meng X, Li S, Dai H, et al. JAMA. 2024;332(17):1437-1445. doi:10.1001/jama.2024.14721.
4. Intravenous Tenecteplase Compared With Alteplase for Acute Ischaemic Stroke in Canada (AcT): A Pragmatic, Multicentre, Open-Label, Registry-Linked, Randomised, Controlled, Non-Inferiority Trial. Menon BK, Buck BH, Singh N, et al. Lancet (London, England). 2022;400(10347):161-169. doi:10.1016/S0140-6736(22)01054-6.
5. Stroke. Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Lancet (London, England). 2024;403(10446):2820-2836. doi:10.1016/S0140-6736(24)00642-1.
6. Tenecteplase Versus Alteplase in Acute Ischaemic Cerebrovascular Events (TRACE-2): A Phase 3, Multicentre, Open-Label, Randomised Controlled, Non-Inferiority Trial. Wang Y, Li S, Pan Y, et al. Lancet (London, England). 2023;401(10377):645-654. doi:10.1016/S0140-6736(22)02600-9.

-------------------------------------------


10. “In severe asthma with eosinophilic phenotype and frequent exacerbations despite high‑dose ICS/LABA, how should clinicians choose between mepolizumab, benralizumab, dupilumab, and tezepelumab based on biomarker profiles (eosinophils, FeNO, IgE), comorbidities, and head‑to‑head or indirect comparative evidence?”

Severe asthma with an eosinophilic phenotype and frequent exacerbations despite high-dose inhaled corticosteroids and long-acting beta agonists is defined by persistent symptoms, ≥2 exacerbations/year, and blood eosinophil count (BEC) typically ≥150 cells/μL, after confirming adherence and excluding mimickers or comorbidities.[1][2]  
  
Mepolizumab (anti-IL-5, 100 mg SC q4w), benralizumab (anti-IL-5Rα, 30 mg SC q4w ×3 then q8w), dupilumab (anti-IL-4Rα, 200–300 mg SC q2w), and tezepelumab (anti-TSLP, 210 mg SC q4w) are FDA-approved for add-on maintenance in severe asthma; mepolizumab and benralizumab are indicated for eosinophilic granulomatosis with polyangiitis (EGPA), and mepolizumab for hypereosinophilic syndrome and chronic rhinosinusitis with nasal polyps.[2][3][4]  
  
**Selection among these biologics is primarily guided by biomarker profiles:**  
  
- **Blood eosinophil count (BEC):** Higher BEC (≥300–500 cells/μL) predicts greater response to anti-IL-5/IL-5R agents (mepolizumab, benralizumab). Mepolizumab shows greatest exacerbation reduction at BEC ≥500 cells/μL, but is effective at ≥150 cells/μL; benralizumab is effective at ≥300 cells/μL, but also benefits lower counts. Dupilumab and tezepelumab are effective across a broader BEC range, including [1][2][5][6][7][8][9]  
  
- **Fractional exhaled nitric oxide (FeNO):** Elevated FeNO (≥25 ppb) predicts better response to dupilumab and tezepelumab, reflecting type 2 inflammation. Tezepelumab is effective regardless of FeNO, but higher FeNO may indicate greater benefit.[1][9]  
  
- **Immunoglobulin E (IgE):** IgE is not a selection criterion for these agents, except for omalizumab (not included in this comparison). Dupilumab is preferred in patients with comorbid atopic dermatitis or allergic rhinitis, but does not require elevated IgE.[3][4]  
  
**Comparative efficacy from network meta-analyses and indirect comparisons:**  
  
- **Exacerbation reduction:** Tezepelumab and dupilumab are associated with greater reductions in exacerbation rates than benralizumab or mepolizumab, especially at lower BEC ([7][8][9][10]  
  
- **Lung function (FEV1):** Dupilumab and tezepelumab yield greater improvements in FEV1 than mepolizumab or benralizumab, though differences are below clinically important thresholds.[7][10][8]  
  
- **Asthma control and quality of life:** Mepolizumab may provide the greatest improvement in Asthma Control Questionnaire scores, but differences among agents are small.[10][8]  
  
**Comorbidities and special populations:**  
  
- **Chronic rhinosinusitis with nasal polyps:** Mepolizumab, benralizumab, and dupilumab have evidence for benefit; dupilumab is also indicated for atopic dermatitis and eosinophilic esophagitis.[1][2][3][4]  
  
- **Oral corticosteroid dependence:** Mepolizumab, benralizumab, and dupilumab have demonstrated steroid-sparing effects; mepolizumab and benralizumab are preferred in patients with BEC ≥500 cells/μL and regular oral corticosteroid use due to risk of hypereosinophilia with dupilumab.[1]  
  
- **Allergic phenotype:** Dupilumab is preferred in patients with prominent allergic comorbidities; anti-IL-5/IL-5R agents are effective regardless of allergic status.[2][4]  
  
**Safety, adverse events, and practical considerations:**  
  
- All agents have favorable safety profiles; injection site reactions, headache, and nasopharyngitis are common. Dupilumab may cause transient blood eosinophilia and conjunctivitis; benralizumab may increase risk of helminthic infections. Self-administration is available for all agents; dosing frequency and payer criteria may influence choice.[2][4]  
  
**Limitations and gaps in evidence:**  
  
- There are no direct head-to-head randomized controlled trials comparing these agents; most data are from network meta-analyses and indirect comparisons. Real-world studies and pragmatic trials are needed to clarify optimal sequencing and remission rates.[5][8]  
  
In summary, **mepolizumab and benralizumab are preferred for patients with high blood eosinophil counts and oral corticosteroid dependence; dupilumab and tezepelumab are favored for broader biomarker profiles, including lower eosinophil counts and elevated FeNO, with dupilumab preferred in those with allergic comorbidities or nasal polyps. Tezepelumab is the only agent with proven efficacy in non-eosinophilic asthma. Safety, comorbidities, dosing, and payer criteria should also inform selection**.[1][2][3][4][7][10][8][9]  
  
  
Would you like me to summarize the latest real-world effectiveness and safety data for these biologics, especially regarding long-term outcomes and optimal sequencing or switching strategies in severe asthma? This could help guide decisions beyond clinical trial results and indirect comparisons.  
  
### References

1. Anti-Cytokine Biologics for Asthma in Adults. Israel E, Wechsler ME, Jackson DJ, Moore WC. Lancet (London, England). 2025;406(10516):2282-2294. doi:10.1016/S0140-6736(25)01625-3.
2. 2025 GINA Severe Asthma Guide Diagnosis and Management of Difficult-to-treat & Severe Asthma. Helen Reddel, Eric Bateman, Gerard FitzGerald, et al. Global Initiative for Asthma.
3. FDA Orange Book. FDA Orange Book.
4. Biologic Therapies for Severe Asthma. Brusselle GG, Koppelman GH. The New England Journal of Medicine. 2022;386(2):157-171. doi:10.1056/NEJMra2032506.
5. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, et al. Global Initiative for Asthma.
6. Management of Severe Asthma: A European Respiratory Society/American Thoracic Society Guideline. Holguin F, Cardet JC, Chung KF, et al. The European Respiratory Journal. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019.
7. Comparative Efficacy of Tezepelumab to Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-Analysis. Nopsopon T, Lassiter G, Chen ML, et al. The Journal of Allergy and Clinical Immunology. 2023;151(3):747-755. doi:10.1016/j.jaci.2022.11.021.
8. Head-to-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?. Lipworth BJ, Greig R, Chan R, Kuo CR, Jackson C. Allergy. 2025;80(5):1226-1241. doi:10.1111/all.16537.
9. Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients With Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. Ando K, Fukuda Y, Tanaka A, Sagara H. Cells. 2022;11(5):819. doi:10.3390/cells11050819.
10. Comparative Efficacy of Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-Analysis. Akenroye A, Lassiter G, Jackson JW, et al. The Journal of Allergy and Clinical Immunology. 2022;150(5):1097-1105.e12. doi:10.1016/j.jaci.2022.05.024.